Redmond’s EndoGastric Solutions (EGS), a leader in incisionless procedural therapy for gastroesophageal reflux disease (GERD), announced three new appointments to its executive team: Mike Zagger — vice president, sales and marketing; Philip Macdonald — vice president of health-care economics, policy and reimbursement; and Adrian Lobontiu — medical director.

“These new appointments reflect our company’s leadership position in the GERD market and our deep commitment to building a balanced commercial organization. Our objective is to provide greater access of the TIF (transoral incisionless fundoplication) procedure to the medical community and the patients they serve,” said Skip Baldino, president and CEO of EGS.

“With a significant body of clinical evidence supporting the TIF procedure, multiple recent EsophyX device product clearances, and the AMA approval of a new Category 1 CPT code effective January 1, 2016, we are poised to scale our business. The addition of these seasoned health-care executives will enable us to maximize our commercialization plans and bring optimal value to the GERD medical community,” concluded Baldino.

The EsophyX device was FDA cleared in 2007, and is commercially available in the United States. Inserted through the patient’s mouth with visual guidance from an endoscope, the EsophyX device is used to reconstruct the gastroesophageal valve (GEV) in order to restore its function as a barrier to prevent stomach acids from washing back up into the esophagus.